๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Delhi
Clinical trial register · India

Clinical Trials in Delhi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca40 Bristol-Myers Squibb6 Novo Nordisk A/S6 Novartis Pharmaceuticals4 All India Institute of Medical Sciences3
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
97 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
NCT06080789Acute Pancreatitis
Panafina, Inc.
Phase 2
36
Kochi, Vellore, Chandigarh, Delhi, New Delhi
2024-06-28
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow, Mumbai
2024-06-20
Recruiting
Safety & Efficacy of Eyecyte-RPEโ„ข in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
NCT06394232Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
Eyestem Research Pvt. Ltd.
Phase 1/2
54
Jฤlna, Delhi, Hyderabad
2024-06-04
Recruiting
Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation
NCT06323330Stroke Rehabilitation, Aphasia, Broca
All India Institute of Medical Sciences
Not applicable
60
New Delhi, Delhi
2024-06-01
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Bengaluru, Chandigarh, Delhi, Gurgaon, Mangaluru, Nagpur, New Delhi, Thiruvananthapuram
2024-04-16
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Ahmedabad, Ajmer, Amritsar, Bangalore, Belagavi, Coimbatore, Dehradun, Delhi
2024-04-12
Recruiting
Dose Escalation Using Hypoxia-adjusted Radiotherapy
NCT06087614Head and Neck Squamous Cell Carcinoma
Rajiv Gandhi Cancer Institute & Research Center, India
Phase 2
124
Delhi
2024-04-08
Recruiting
The PURI-HF (Air Purifiers on Heart Failure) Trial
NCT05230784Heart Failure
NYU Langone Health
Not applicable
255
Thiruvananthapuram, Delhi, Ludhiana
2024-03-06
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Ahmedabad, Aligarh, Belagavi, Calicut, Chandigarh, Dehradun, Delhi, Dwฤrka
2024-02-21
Recruiting
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
NCT06412250Cardiovascular Diseases
Translumina Therapeutics Pvt Ltd.
Observational
2,000
Ahmedabad, Bangalore, Bathinda, Chandigarh, Delhi, Gurugram, Hyderabad, Jabalpur
2024-01-10
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Gandhinagar, Gurugramam, Jhajjar, Bangalore, Mysuru, Navi Mumbai, Pune, Delhi
2023-12-20
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Bangalore, Belagavi, Delhi, Nadiฤd, New Delhi
2023-11-07
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Ansฤrinagar, Bangalore, Dehradun, Delhi, Kolkata, Kozhikode, Mumbai, Mysuru
2023-10-05
Recruiting
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
NCT07062263Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer, Unresectable Biliary Tract Carcinoma
Tata Memorial Centre
Phase 3
220
Muzaffarpur, Mumbai, Bhubaneswar, Mลซllฤnpur, Varanasi, Delhi
2023-07-21
Recruiting
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
NCT05953584Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 2
27
Raipur, Delhi, Gujarat, Maharashtra, Nagpur
2023-06-20
Active, closed
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (ฮฒ-Thal) in India
NCT05891249Anemia
Bristol-Myers Squibb
Phase 4
85
Ahmedabad, New Delhi, Kolkata, Assam, Bangalore, Chandigarh, Delhi, Hyderabad
2023-06-05
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Sociรฉtรฉ Internationale d'Urologie
Observational
7,500
Delhi
2023-03-13
Active, closed
Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
NCT03775460Erythema Nodosum Leprosum
London School of Hygiene and Tropical Medicine
Not applicable
550
Delhi, Mumbai
2023-01-15
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Calicut, Delhi, Jaipur, Kolkata, Madurai, Puducherry
2022-12-29
Rows per page Showing 51–75 of 97
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.